Trials / Completed
CompletedNCT02140346
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Inhaled RV1729 in Patients With COPD
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Respivert Ltd · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The objective of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics repeat doses of RV1729 in patients with COPD for 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RV1729 28 day repeat dose | Safety and tolerability of repeat doses |
| DRUG | RV1729 matching placebo 28 day repeat dose | Safety and tolerability of repeat doses |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2014-05-16
- Last updated
- 2015-07-02
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02140346. Inclusion in this directory is not an endorsement.